The United States Food and Drug Administration (FDA) has fundamentally altered the landscape of medical device marketing submissions by shifting the focus from isolated validation testing to a comprehensive, process-oriented approach to usability engineering. Central to this transition is the FDA’s 2026 human factors content guidance, which is now formally integrated into the eSTAR v7.0 electronic submission template. For medical device manufacturers, this represents a significant regulatory evolution. The core inquiry from regulators is no longer simply whether a device was tested, but whether the manufacturer has systematically identified, analyzed, and mitigated use-related risks to an acceptable level. Under the new framework, human factors (HF) validation is viewed not as an independent hurdle to be cleared at the end of development, but as a potential output of a rigorous usability engineering file that must be documented throughout the product lifecycle.
The Shift from Validation Reports to Usability Engineering Files
Historically, many medical device manufacturers approached human factors as a late-stage deliverable—a "check-the-box" exercise completed just prior to submission. The prevailing questions among industry stakeholders often centered on the necessity and methodology of a validation study. However, the FDA’s current stance emphasizes that the absence of a validation study does not equate to an absence of human factors requirements. If foreseeable misuse of a device could lead to severe harm for a patient or user, validation testing is generally mandatory to prove that risk controls are effective. Conversely, if a manufacturer argues that such testing is unnecessary, they must provide a robust, evidence-based justification within a comprehensive usability engineering file.
The integration of these requirements into the eSTAR v7.0 template means that manufacturers who have not previously been required to submit detailed human factors data may now face additional documentation burdens. For devices that were traditionally cleared based on predicate comparisons, the FDA now expects a deeper dive into how modifications or specific use environments affect safety. This shift forces a change in the definition of "submission-ready," requiring engineering and regulatory teams to collaborate much earlier in the design phase.
A Risk-Based Hierarchy: Understanding the Three Submission Categories
The FDA has categorized medical device human factors submissions into three distinct tiers, determined primarily by the potential for use-related harm and the complexity of user interaction, rather than by product code alone.
- Category 1: Reserved for devices where the changes are minor or the risk of use-related harm is negligible. These submissions require the least amount of human factors documentation.
- Category 2: Applies to devices where use errors could lead to moderate harm or where the manufacturer must provide a detailed justification for why a full validation study is not necessary.
- Category 3: Mandatory for devices where use-related errors could result in serious harm or death. These require a full human factors validation study (often referred to as summative testing).
The distinction between Category 2 and Category 3 is a frequent point of contention and strategic planning for manufacturers. The transition between these categories is often triggered by modifications to an existing device. For instance, a home-use in vitro diagnostic (IVD) might be classified as Category 2 if a misread result only leads to minor delays in care or temporary discomfort. However, if that same device is modified for use in a high-stakes clinical environment where a misdiagnosis could lead to incorrect surgical intervention or the administration of a contraindicated drug, the device may be elevated to Category 3. In such cases, the FDA evaluates whether the user interface deviates from the established "standard of care." If the interface is novel or potentially confusing to clinicians, the burden of proof for safety increases significantly.
Chronology of Human Factors Regulatory Evolution
The current regulatory environment is the result of over a decade of incremental policy shifts aimed at reducing medical errors.
- 2011–2016: The FDA released draft and eventually final guidance on "Applying Human Factors and Usability Engineering to Medical Devices." This period established the basic expectation that manufacturers should consider the user interface in their design controls.
- 2022: The FDA issued a new draft guidance titled "Content of Human Factors Information in Medical Device Marketing Submissions." This draft introduced the three-category framework and sought to clarify exactly what documents should be included in a 510(k), PMA, or De Novo submission.
- 2023–2024: The principles of the 2022 draft guidance began to be enforced more strictly during the review process. The FDA also updated the eSTAR (electronic Submission Template and Resource) to version 7.0, which includes specific, mandatory fields for human factors data based on the device’s risk profile.
- 2026 Target: The full implementation of the 2026 guidance serves as the definitive benchmark for industry compliance, marking the point where "showing your work" becomes as important as the final safety data.
The Required Evidence: URRA, KUPS, and Use Specifications
Under the new guidance, the FDA expects a specific set of documents to support a Category 2 or Category 3 claim. The burden of proof rests entirely on the sponsor, and mere assertions of safety are no longer sufficient.
Use-Related Risk Analysis (URRA): This is now expected for nearly every new device submission. A URRA identifies every possible task a user must perform and analyzes the potential for error in each step. Manufacturers must identify "critical tasks"—those where an error could result in serious harm. The presence of critical tasks almost always necessitates a Category 3 classification and a subsequent validation study.
Known Use Problem Search (KUPS): This report is a systematic review of public databases, such as the FDA’s MAUDE (Manufacturer and User Facility Device Experience) database. Manufacturers must identify foreseeable misuses and adverse events associated with similar devices already on the market. The KUPS provides a baseline of "real-world" risks that the new device’s design must address.
Use Specification: This document outlines the intended users (e.g., age, education level, physical limitations), the intended use environment (e.g., sterile OR, noisy ambulance, home setting), and the required training. The FDA uses this to determine if the manufacturer’s testing environment accurately reflects the reality of the device’s end-use.
Integrating Usability into Clinical Trials
While standalone human factors validation studies are the norm for Category 3 devices, the FDA does allow for usability evidence to be gathered during clinical trials under specific, narrow conditions. This approach is often utilized for devices where simulated use testing is insufficient—such as ablation devices that require real-time physiological feedback or complex surgical tools used on a beating heart.
However, the FDA has established strict caveats for this "integrated" approach. The usability protocol must be built into the clinical study design from the outset; it cannot be an afterthought or a retrospective analysis of clinical data. Furthermore, the FDA warns against "over-training" clinical trial participants. If participants receive more training than a typical user would in the real world, the usability data is considered compromised. Participants must be observed by trained human factors professionals during the trial to capture use errors that might not be reported as adverse events.
Industry Implications and Strategic Recommendations
The shift toward a more documented usability process has significant implications for product development timelines and costs. Manufacturers who fail to adapt risk receiving "additional information" (AI) requests or deficiency letters, which can delay market entry by months.
For companies with submissions planned in the next 30 to 90 days, the window for a pre-submission meeting with the FDA has closed. In these instances, the priority must be a "gap analysis" of the existing usability engineering file. Manufacturers should ensure that their URRA is comprehensive and that their KUPS report is up to date. If a device is a modification of a legacy product, the FDA now expects a "comparative user interface analysis." Simply stating that "nothing significant changed" is frequently rejected by reviewers. Instead, manufacturers must provide a side-by-side comparison of user tasks and risk controls between the old and new versions.
Industry experts note that the FDA’s increased scrutiny is a response to the rising complexity of medical technology and the move toward home-based healthcare. As patients with varying levels of health literacy interact with sophisticated devices, the potential for catastrophic use error increases. By mandating a "process-first" approach, the FDA aims to ensure that safety is "baked into" the design rather than "tested on" at the end.
Conclusion: The New Standard of Proof
The underlying philosophy of the FDA has not changed: devices must be proven safe and effective. What has changed is the transparency required in that demonstration. The integration of human factors into eSTAR v7.0 and the 2026 guidance represents the end of the era of the "black box" submission, where manufacturers could present a final product without detailing the iterative steps taken to ensure its usability.
For the medical device industry, this evolution requires a cultural shift. Usability engineering must be treated with the same rigor as mechanical or electrical engineering. Companies that invest in robust human factors processes early in development will find the regulatory path smoother, while those who treat it as a late-stage formality will likely face increasing hurdles in the years to come. The message from the FDA is clear: to gain market access, manufacturers must not only create safe devices but must also provide a meticulous paper trail proving how they arrived at that safety.
